title: Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
abstract: BACKGROUND
  Uveal melanoma exhibits a high incidence of metastases; and, to date, there is no systemic therapy that clearly improves outcomes. The anticytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody ipilimumab is a standard of care for metastatic melanoma; however, the clinical activity of CTLA-4 inhibition in patients with metastatic uveal melanoma is poorly defined.
  
  
  METHODS
  To assess ipilimumab in this setting, the authors performed a multicenter, retrospective analysis of 4 hospitals in the United States and Europe. Clinical characteristics, toxicities, and radiographic disease burden, as determined by central, blinded radiology review, were evaluated.
  
  
  RESULTS
  Thirty-nine patients with uveal melanoma were identified, including 34 patients who received 3 mg/kg ipilimumab and 5 who received 10 mg/kg ipilimumab. Immune-related response criteria and modified World Health Organization criteria were used to assess the response rate (RR) and the combined response plus stable disease (SD) rate after 12 weeks, after 23 weeks, and overall (median follow-up, 50.4 weeks [12.6 months]). At week 12, the RR was 2.6%, and the response plus SD rate was 46.%; at week 23, the RR was 2.6%, and the response plus SD rate was 28.2%. There was 1 complete response and 1 late partial response (at 100 weeks after initial SD) for an immune-related RR of 5.1%. Immune-related adverse events were observed in 28 patients (71.8%) and included 7 (17.9%) grade 3 and 4 events. Immune-related adverse events were more frequent in patients who received 10 mg/kg ipilimumab than in those who received 3 mg/kg ipilimumab. The median overall survival from the first dose of ipilimumab was 9.6 months (95% confidence interval, 6.3-13.4 months; range, 1.6-41.6 months). Performance status, lactate dehydrogenase level, and an absolute lymphocyte count ≥ 1000 cells/μL at week 7 were associated significantly with survival.
  
  
  CONCLUSIONS
  In this multicenter, retrospective analysis of 4 hospitals in the United States and Europe of patients with uveal melanoma, durable responses to ipilimumab and manageable toxicity were observed.
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
authors.forename: Jason J
authors.initials: JJ
authors.lastname: Luke
authors.forename: Margaret K
authors.initials: MK
authors.lastname: Callahan
authors.forename: Michael A
authors.initials: MA
authors.lastname: Postow
authors.forename: Emanuela
authors.initials: E
authors.lastname: Romano
authors.forename: Nikhil
authors.initials: N
authors.lastname: Ramaiya
authors.forename: Mark
authors.initials: M
authors.lastname: Bluth
authors.forename: Anita
authors.initials: A
authors.lastname: Giobbie-Hurder
authors.forename: Donald P
authors.initials: DP
authors.lastname: Lawrence
authors.forename: Nageatte
authors.initials: N
authors.lastname: Ibrahim
authors.forename: Patrick A
authors.initials: PA
authors.lastname: Ott
authors.forename: Keith T
authors.initials: KT
authors.lastname: Flaherty
authors.forename: Ryan J
authors.initials: RJ
authors.lastname: Sullivan
authors.forename: James J
authors.initials: JJ
authors.lastname: Harding
authors.forename: Sandra
authors.initials: S
authors.lastname: D'Angelo
authors.forename: Mark
authors.initials: M
authors.lastname: Dickson
authors.forename: Gary K
authors.initials: GK
authors.lastname: Schwartz
authors.forename: Paul B
authors.initials: PB
authors.lastname: Chapman
authors.forename: Jedd D
authors.initials: JD
authors.lastname: Wolchok
authors.forename: F Stephen
authors.initials: FS
authors.lastname: Hodi
authors.forename: Richard D
authors.initials: RD
authors.lastname: Carvajal
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors* / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000074324:Ipilimumab; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D015996:Survival Rate; D014495:Universities; D014604:Uveal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000098943:Uveal Melanoma
chemical_list: D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; D000074324:Ipilimumab
keywords: absolute lymphocyte count; cytotoxic T-lymphocyte-associated protein 4; immunotherapy; ipilimumab; uveal melanoma
references.citation: J Immunotoxicol. 2008 Apr;5(2):201-7
references.pmid: 18569391
references.citation: Ann Oncol. 2013 Jun;24(6):1697-703
references.pmid: 23439861
references.citation: N Engl J Med. 2010 Aug 19;363(8):711-23
references.pmid: 20525992
references.citation: Melanoma Res. 2013 Feb;23(1):79-81
references.pmid: 23211837
references.citation: PLoS One. 2012;7(11):e48787
references.pmid: 23226204
references.citation: Arch Ophthalmol. 1996 Jan;114(1):107-8
references.pmid: 8540843
references.citation: Nature. 2009 Jan 29;457(7229):599-602
references.pmid: 19078957
references.citation: Cancer Immunol Immunother. 2012 Jan;61(1):41-8
references.pmid: 21833591
references.citation: Lancet Oncol. 2010 Feb;11(2):155-64
references.pmid: 20004617
references.citation: Br J Cancer. 2002 Oct 7;87(8):840-5
references.pmid: 12373596
references.citation: Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4651-9
references.pmid: 14578381
references.citation: J Clin Oncol. 2005 Nov 1;23(31):8076-80
references.pmid: 16258106
references.citation: Lancet Oncol. 2012 Aug;13(8):782-9
references.pmid: 22805292
references.citation: Ophthalmology. 2003 May;110(5):956-61
references.pmid: 12750097
references.citation: Br J Cancer. 2009 Sep 1;101(5):813-5
references.pmid: 19654573
references.citation: Cancer. 1995 Nov 1;76(9):1665-70
references.pmid: 8635073
references.citation: Clin Cancer Res. 2011 Oct 15;17(20):6574-81
references.pmid: 21880788
references.citation: Clin Cancer Res. 2009 Sep 1;15(17):5591-8
references.pmid: 19671877
references.citation: Melanoma Res. 1998 Feb;8(1):11-6
references.pmid: 9508371
references.citation: Cancer. 2010 Apr 1;116(7):1767-75
references.pmid: 20143434
references.citation: Br J Cancer. 1998 Nov;78(9):1156-61
references.pmid: 9820172
references.citation: J Pediatr Hematol Oncol. 2002 Aug-Sep;24(6):488-91
references.pmid: 12218599
references.citation: J Transl Med. 2011 Nov 13;9:196
references.pmid: 22077981
references.citation: Eur J Surg Oncol. 1998 Apr;24(2):127-30
references.pmid: 9591028
references.citation: Clin Cancer Res. 2009 Dec 1;15(23):7412-20
references.pmid: 19934295